To note, when adding the clinico-pathologic variables tumor diameter, histologic grade, lymph node status, and MKI67 to the multivariate analysis (< 50 METABRIC discovery and validation cohorts, n = 368), AURKA mRNA demonstrated independent association with shorter disease-specific survival (P < 0.001, HR = 2.25 95% CI 1.63–3.10 and HR = 2.21 95% CI 1.50–3.26 respectively) for patients aged 40–49 years (Supplementary Table 1). Here, AURKA is linked to neoplasm.